S309
An anti Spike (SARS-CoV/SARS-CoV-2) antibody.
General information
S309 is a monoclonal antibody identified in a memory B cell from a SARS-CoV patient. It has potent neutralizing capacity against SARS-CoV-2. It interacts with a Spike protein epitope (Pinto et al., 2020).
It is the parental antibody of sotrovimab.
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Cryo-EM Crystallization In vitro |
in vitro binding assay; cryo-EM; crystallization; HEK293T cells; Vero E6 cells; SARS-CoV-2 pseudovirus; SARS-CoV-2 strain 2019-nCoV/USA_WA1/2020 | 42.78 | The antibody neutralizes live SARS-CoV-2 with an IC50 of 79 ng/ml in vitro. S309-mediated neutralization can be potentiated by other antibodies (which themselves are only weakly neutralizing – e.g. S304 an S315). |
May/18/2020 |
|
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Spike protein Spike variant Protein factor In vitro Antibody |
Vero-TMPRSS2 cells; Vero-hACE2-TMPRSS2 cells; SARS-CoV-2 strains WA1/2020 and hCoV-19/USA/WI-WSLH-221686/2021 (Omicron) | 53.44 | The antibody’s capacity to neutralize B.1.1.529 (Omicron) variant of SARS-CoV-2 was not significantly reduced in vitro. |
Jan/19/2022 |
|
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
Spike protein Spike variant Cryo-EM Crystallization Biophysical assay Protein factor In vitro Antibody |
In vitro | 47.73 | The antibody’s affinity for B.1.1.529 (Omicron) variant Spike of SARS-CoV-2 was only modestly reduced in vitro. It was observed to bind an epitope not significantly affected be emergent mutations. |
Jan/25/2022 |
|
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Spike protein Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody In silico |
Vero E6 cells; Vero E6-hACE2(-TMPRSS2) cells; (VSV) SARS-CoV-2 Spike-pseudotyped virus | 41.58 | Neutralizes Spike variants N439K, K417V, and N439K/K417V in vitro. |
Mar/04/2021 |
|
A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants
Spike protein ACE2 Spike variant Cryo-EM Protein factor Animal model In vitro Mechanism Antibody |
Huh-7 cells; hACE2 mice; (VSV) SARS-CoV-2 Spike-pseudotyped virus (various strains) | 18.19 | Although the antibody was not observed to interfere with RBD (SARS-CoV-2 Spike) binding to ACE2, it did retain some of its capacity to neutralize the virus. |
Jan/25/2022 |
|
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Spike protein Spike variant Protein factor In vitro Antibody |
Vero E6-TMPRSS2 cells; SARS-CoV-2 strains (SARS-CoV-2/UT-NC002-1T/Human/2020/Tokyo, alpha, beta, gamma, delta, omicron) | 91.25 | S309 neutralizes the omicron strain of SARS-CoV-2 in vitro, although with a higher FRNT50. |
Jan/26/2022 |
|
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Spike protein ACE2 RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
sera from vaccinated or convalescent individuals; VeroE6/TMPRSS2 cells; SARS-CoV-2 (various strains) | 41.58 | Neutralizes Omicron variant in vitro. |
Jan/04/2022 |
|
Antibody evasion by the P.1 strain of SARS-CoV-2
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Gamma) | 41.58 | Neutralized all of the SARS-CoV-2 strains tested in vitro. The antibody was not able to completely neutralize the Gamma strain, however. |
Mar/30/2021 |
|
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Spike protein RNA DNA Spike variant Crystallization Biophysical assay Protein factor In vitro Antibody Mixed substance |
in vitro biophysical assay; crystallization; sera of COVID-19 convalescent patients and vaccinated adults; Vero cells; HEK293T/17-hACE2 cells; SARS-CoV-2 (Victoria, Alpha, Beta, and Delta); (HIV-1) SARS-CoV-2 Spike-pseudotyped virus (various variants) | 41.58 | The antibody neutralized the Delta variant of SARS-CoV-2 in vitro. |
Jun/17/2021 |
|
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
Spike protein Spike variant Protein factor In vitro Antibody |
HEK293T cells; HEK293T-ACE2 cells; (lentiviral/HIV) SARS-CoV-2 pseudotyped viruses (D614G, Beta, Mu, Delta and Omicron strains) | 25.07 | Only a two-fold reduction in neutralization potency of the Omicron strain was observed for the antibody in vitro. |
Jun/22/2022 |
|
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
3CLpro Spike variant Protein factor Small molecule Animal model In vitro Antibody |
VeroE6/TMPRSS2 cells; Syrian hamsters (K18-hACE2 lines); K18-hACE2 C57BL/6J mice; BALB/c mice; SARS-CoV-2 live virus (D614G, Delta, Omicron BA.1, Omicron BA.1.1, and Omicron BA.2 (various isolates)) | 49.96 | The antibody administered on day one post Syrian hamster viral challenge significantly decreased the viral titres of SARS-CoV-2 Omicron BA.2 in animals’ lungs. No significant decrease was observed in the case of nasal turbinates, however. |
May/16/2022 |
